Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
Cicin İ, Özatlı T, Türkmen E, Özturk T, Özçelik M, Çabuk D, Gökdurnalı A, Balvan Ö, Yıldız Y, Şeker M, Özdemir N, Yapar B, Tanrıverdi Ö, Günaydin Y, Menekşe S, Öksüzoğlu B, Aksoy A, Erdogan B, Bekir Hacıoglu M, Arpaci E, Sevinç A. Cicin İ, et al. Among authors: seker m. Balkan Med J. 2016 Sep;33(5):517-524. doi: 10.5152/balkanmedj.2016.151268. Epub 2016 Sep 1. Balkan Med J. 2016. PMID: 27761279 Free PMC article.
Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology.
Arpaci E, Yetisyigit T, Seker M, Uncu D, Uyeturk U, Oksuzoglu B, Demirci U, Coskun U, Kucukoner M, Isıkdogan A, Inanc M, Alkis N, Ozkan M. Arpaci E, et al. Among authors: seker m. Med Oncol. 2013 Mar;30(1):469. doi: 10.1007/s12032-013-0469-z. Epub 2013 Jan 24. Med Oncol. 2013. PMID: 23345116
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: seker m. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778
Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O, Inanc M, Hacibekıroglu I, Esbah O, Seker M, Ulas A, Aydin K, Uysal M, Kücüköner M, Uncu D, Cıltas A, Unal OÜ, Durnali A, Demırcı U, Berk V, Tonyali O, Oksüzoglu B, Karaca H, Ozkan M. Bozkurt O, et al. Among authors: seker m. Anticancer Res. 2014 Aug;34(8):4463-70. Anticancer Res. 2014. PMID: 25075086
267 results